Drug intelligence / Profile preview

lipustobart

Development stage: Phase 1
Lead developer: Livzon Monoclonal Antibody
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous

Overview

Lipustobart (LZM009) is a human IgG4 monoclonal antibody that binds to PD-1 molecules on the surface of T-cells, blocks the PD-1/PD-Ligand 1 (PD-L1) pathway, and reactivates T cells to kill cancer cells. It was developed by Livzon Pharmaceutical Group through its subsidiary Livzon Mabpharm. The drug has completed clinical dose exploration trials in both China and the United States and has undergone extensive clinical trials, including pivotal trials in thymic cancer in China, with promising initial safety and efficacy data.

Other names: lipustobart利普苏拜单抗

Targets

PDCD1 (Programmed cell death protein 1 receptor)

Beyond the preview

Go deeper on lipustobart.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on lipustobart.

Explore the full profile